Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q1 2020 · 10-Q
Revenue$687.96K$687.96K— vs Q1 2019 Net Income$81.12K$81.12KN/M vs Q1 2019 EPS Diluted$0.00$0.00— vs Q1 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
$81,557
N/M
Operating Cash Flow-$26,014N/M Margins · derivedGross margin23.2%
Operating margin11.9%
Net margin11.8%
ended Mar 31, 2020 · filed May 19, 2020 · 49 d after period end